Two issues with your take.
First 'fully funded' as used by you, is a relative term and not reflective of any long term reality for Incannex. The 33M they had at last reporting represented roughly 15% of what their pipelines would probably require BEFORE the APIRx acquisition, which of course greatly expanded their pipeline array.
Second, you ask why not wait until 2023 trial results to see some SP appreciation. The answer is pretty simple:
a) positive trial results are not guaranteed, and they would be execrable management to gamble the future of the entire company on a single set of trial results. They have the biggest cannabinoid IP portfolio in the world. It is all good and well to be bullish and have tunnel-vision around ILH-42x, but not to the degree that the entire company is thrown on the pile.
b) plenty of forecasts are mentioning further downside for 2023, with a slow recovery in 2024, particularly for US and economies attached to it. According to that scenario, current SP may indeed seem quite favourable in the mid term future.
- Forums
- ASX - By Stock
- Ann: Incannex Undertakes A$13 Million Institutional Placement
Two issues with your take.First 'fully funded' as used by you,...
-
- There are more pages in this discussion • 182 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IHL (ASX) to my watchlist
Currently unlisted public company.
The Watchlist
SER
STRATEGIC ENERGY RESOURCES LIMITED
David DeTata, Managing Director
David DeTata
Managing Director
SPONSORED BY The Market Online